Switch to:
Also traded in: Argentina, Austria, Brazil, Chile, Germany, Mexico, Switzerland, UK

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 7/10

vs
industry
vs
history
Cash-to-Debt 1.22
NYSE:JNJ's Cash-to-Debt is ranked lower than
56% of the 815 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.12 vs. NYSE:JNJ: 1.22 )
Ranked among companies with meaningful Cash-to-Debt only.
NYSE:JNJ' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.15  Med: 1.36 Max: N/A
Current: 1.22
Equity-to-Asset 0.49
NYSE:JNJ's Equity-to-Asset is ranked lower than
70% of the 739 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 0.63 vs. NYSE:JNJ: 0.49 )
Ranked among companies with meaningful Equity-to-Asset only.
NYSE:JNJ' s Equity-to-Asset Range Over the Past 10 Years
Min: 0.44  Med: 0.54 Max: 0.67
Current: 0.49
0.44
0.67
Interest Coverage 27.62
NYSE:JNJ's Interest Coverage is ranked lower than
62% of the 638 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 118.48 vs. NYSE:JNJ: 27.62 )
Ranked among companies with meaningful Interest Coverage only.
NYSE:JNJ' s Interest Coverage Range Over the Past 10 Years
Min: 27.62  Med: 36.54 Max: 46.15
Current: 27.62
27.62
46.15
Piotroski F-Score: 6
Altman Z-Score: 5.29
Beneish M-Score: -2.49
WACC vs ROIC
6.00%
30.09%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 7/10

vs
industry
vs
history
Operating Margin % 29.47
NYSE:JNJ's Operating Margin % is ranked higher than
92% of the 767 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 7.94 vs. NYSE:JNJ: 29.47 )
Ranked among companies with meaningful Operating Margin % only.
NYSE:JNJ' s Operating Margin % Range Over the Past 10 Years
Min: 22.36  Med: 25.94 Max: 29.47
Current: 29.47
22.36
29.47
Net Margin % 22.87
NYSE:JNJ's Net Margin % is ranked higher than
89% of the 769 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 6.26 vs. NYSE:JNJ: 22.87 )
Ranked among companies with meaningful Net Margin % only.
NYSE:JNJ' s Net Margin % Range Over the Past 10 Years
Min: 14.87  Med: 20.07 Max: 23.01
Current: 22.87
14.87
23.01
ROE % 23.01
NYSE:JNJ's ROE % is ranked higher than
85% of the 792 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 6.84 vs. NYSE:JNJ: 23.01 )
Ranked among companies with meaningful ROE % only.
NYSE:JNJ' s ROE % Range Over the Past 10 Years
Min: 17.02  Med: 23.04 Max: 30.17
Current: 23.01
17.02
30.17
ROA % 11.75
NYSE:JNJ's ROA % is ranked higher than
82% of the 821 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 3.58 vs. NYSE:JNJ: 11.75 )
Ranked among companies with meaningful ROA % only.
NYSE:JNJ' s ROA % Range Over the Past 10 Years
Min: 8.93  Med: 12.23 Max: 15.61
Current: 11.75
8.93
15.61
ROC (Joel Greenblatt) % 107.78
NYSE:JNJ's ROC (Joel Greenblatt) % is ranked higher than
94% of the 807 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 13.07 vs. NYSE:JNJ: 107.78 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
NYSE:JNJ' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: 65.66  Med: 87.89 Max: 119.25
Current: 107.78
65.66
119.25
3-Year Revenue Growth Rate 1.30
NYSE:JNJ's 3-Year Revenue Growth Rate is ranked lower than
64% of the 640 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 5.20 vs. NYSE:JNJ: 1.30 )
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
NYSE:JNJ' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: 1.3  Med: 9.3 Max: 14.8
Current: 1.3
1.3
14.8
3-Year EBITDA Growth Rate 7.70
NYSE:JNJ's 3-Year EBITDA Growth Rate is ranked lower than
53% of the 606 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 9.20 vs. NYSE:JNJ: 7.70 )
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
NYSE:JNJ' s 3-Year EBITDA Growth Rate Range Over the Past 10 Years
Min: -6.6  Med: 11.5 Max: 24.1
Current: 7.7
-6.6
24.1
3-Year EPS without NRI Growth Rate 7.20
NYSE:JNJ's 3-Year EPS without NRI Growth Rate is ranked lower than
51% of the 580 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 7.90 vs. NYSE:JNJ: 7.20 )
Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only.
NYSE:JNJ' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: -8.6  Med: 12.4 Max: 34.2
Current: 7.2
-8.6
34.2
GuruFocus has detected 6 Warning Signs with Johnson & Johnson $NYSE:JNJ.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» NYSE:JNJ's 30-Y Financials

Financials (Next Earnings Date: 2017-07-18)


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Drug Manufacturers » Drug Manufacturers - Major    NAICS: 325412    SIC: 2834
Compare:OTCPK:RHHBY, NYSE:PFE, OTCPK:NVSEF, NYSE:MRK, NYSE:SNY, NYSE:ABBV, OTCPK:BAYZF, OTCPK:GLAXF, NYSE:BMY, NYSE:LLY, NYSE:AZN, OTCPK:ALPMF, OTCPK:OTSKY, OTCPK:CHGCY, OTCPK:DSKYF, OTCPK:OPHLY, OTCPK:CHPTY, OTCPK:PTKFY, OTCPK:SNPHF, NAS:HCM » details
Traded in other countries:JNJ.Argentina, JNJ.Austria, JNJB34.Brazil, JNJ.Chile, JNJ.Germany, JNJ.Mexico, JNJ.Switzerland, 0R34.UK,
Headquarter Location:USA
Johnson & Johnson is a holding company, which is engaged in the research and development, manufacture and sale of products in the health care field within its Consumer, Pharmaceutical and Medical Devices segments.

Johnson & Johnson is the world's largest and most diverse healthcare company. Three divisions make up the company: pharmaceutical, medical devices and diagnostics, and consumer. The drug and device groups represent close to 80% of sales and drive the majority of cash flows for the firm. About half of total revenue is generated within the United States.

Guru Investment Theses on Johnson & Johnson

Ariel Funds Comments on Johnson & Johnson - Sep 28, 2016

Medical giant Johnson & Johnson (NYSE:JNJ) rallied +12.66%, due to a strong earnings report. In April the company beat analysts’ estimates and also raised guidance for the year. Earnings were driven by strong sales of drugs like Stelara and Xarelto. At this point pharmaceuticals are the company’s largest business division—ahead of powerhouses such as medical devices and consumer health products. We think the trajectory of the business continues to point upward.



From John Rogers (Trades, Portfolio)' second quarter 2016 Ariel Global Fund commentary.

Check out John Rogers latest stock trades

Yacktman Funds Comments on Johnson & Johnson - Aug 05, 2016

JNJ (NYSE:JNJ) performed well in the second quarter after delivering solid results. Few companies have the financial strength and product diversity of JNJ, which is why it is one of only two companies in the United States (Microsoft is the other) that commands a triple-A credit rating. We think JNJ can deliver solid growth and strong free cash flow over time.



From Yacktman Focused Fund (Trades, Portfolio) second quarter 2016 commentary.


Check out Donald Yacktman,Yacktman Focused Fund latest stock trades

Charles Brandes Comments on Johnson & Johnson - Oct 21, 2015

Healthcare giant Johnson & Johnson (NYSE:JNJ), which has diverse operations in pharmaceuticals, medical devices, biotechnology and consumer health, has faced potential competition in its pharmaceutical segment and lingering concerns over product recalls and manufacturing issues in its consumer segment. Nonetheless, we believe the company’s fundamentals remain attractive, including its strong competitive position and balance sheet, as well as a history of prudent capital deployment. The company generates approximately 70% of its revenues from businesses which command a #1 or #2 global market share, and 25% from products launched over the last five years. Speaking to the strength of its balance sheet, Johnson & Johnson is one of only four U.S. industrial companies with a AAA credit rating from both S&P and Moody’s.

From Charles Brandes (Trades, Portfolio)' third quarter 2015 commentary, Volatility: Misbehaving—In Action.

Check out Charles Brandes latest stock trades

Top Ranked Articles about Johnson & Johnson

Johnson & Johnson Releases 2016 Health for Humanity Report
Johnson & Johnson to Host Investor Conference Call on Second-Quarter Results
Douglas Wallace, Ph.D., Wins 2017 Dr. Paul Janssen Award for Biomedical Research
Tech Stocks Report Losses for the Week Chevron leads gainers; Walmart tops losers
U.S. market indexes were mixed on Friday. Read more...
Johnson & Johnson Announces Completion of Acquisition of Actelion
Johnson & Johnson Announces Expected Settlement of Actelion Tender Offer on June 16, 2017
Funds Are Net Sellers of US Stocks, Buyers of Netherlands and Canada Investment managers were seeking nondomestic stocks in the first quarter, and money continues to move abroad in the second
Trends from the first quarter reveal large U.S. funds shied away from domestic stocks as they favored investment in other markets, particularly the Netherlands, Canada and Israel. Read more...
Multiple-Plaintiff Trial Involving J&J Set to Start Trial over the cancer risks associated with talc powder is slated to begin June 5
A multiple-plaintiff trial over the cancer risks associated with Johnson & Johnson's (NYSE:JNJ) talc powder is scheduled to begin June 5. The trial, which will be held in Missouri state court, will be broadcasted by the Courtroom View Network. Read more...
Johnson & Johnson to Participate in the Goldman Sachs 38th Annual Global Healthcare Conference
Buffett Stocks in Focus: Southwest Airlines See the investment prospects of Warren Buffett's holding
(Published on May 25 by Nicholas McCullum) Read more...

Ratios

vs
industry
vs
history
PE Ratio 22.48
JNJ's PE Ratio is ranked higher than
60% of the 561 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 26.96 vs. JNJ: 22.48 )
Ranked among companies with meaningful PE Ratio only.
JNJ' s PE Ratio Range Over the Past 10 Years
Min: 10.5  Med: 17.81 Max: 24
Current: 22.48
10.5
24
Forward PE Ratio 19.01
JNJ's Forward PE Ratio is ranked higher than
51% of the 68 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 19.46 vs. JNJ: 19.01 )
Ranked among companies with meaningful Forward PE Ratio only.
N/A
PE Ratio without NRI 22.48
JNJ's PE Ratio without NRI is ranked higher than
60% of the 558 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 27.64 vs. JNJ: 22.48 )
Ranked among companies with meaningful PE Ratio without NRI only.
JNJ' s PE Ratio without NRI Range Over the Past 10 Years
Min: 10.5  Med: 17.81 Max: 24
Current: 22.48
10.5
24
Price-to-Owner-Earnings 22.22
JNJ's Price-to-Owner-Earnings is ranked higher than
66% of the 304 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 33.00 vs. JNJ: 22.22 )
Ranked among companies with meaningful Price-to-Owner-Earnings only.
JNJ' s Price-to-Owner-Earnings Range Over the Past 10 Years
Min: 10.19  Med: 17.43 Max: 25.26
Current: 22.22
10.19
25.26
PB Ratio 5.17
JNJ's PB Ratio is ranked lower than
76% of the 761 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.88 vs. JNJ: 5.17 )
Ranked among companies with meaningful PB Ratio only.
JNJ' s PB Ratio Range Over the Past 10 Years
Min: 2.68  Med: 3.71 Max: 5.26
Current: 5.17
2.68
5.26
PS Ratio 5.14
JNJ's PS Ratio is ranked lower than
67% of the 743 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.96 vs. JNJ: 5.14 )
Ranked among companies with meaningful PS Ratio only.
JNJ' s PS Ratio Range Over the Past 10 Years
Min: 2.16  Med: 3.22 Max: 5.25
Current: 5.14
2.16
5.25
Price-to-Free-Cash-Flow 22.73
JNJ's Price-to-Free-Cash-Flow is ranked higher than
56% of the 209 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 25.35 vs. JNJ: 22.73 )
Ranked among companies with meaningful Price-to-Free-Cash-Flow only.
JNJ' s Price-to-Free-Cash-Flow Range Over the Past 10 Years
Min: 10.29  Med: 16.44 Max: 24.34
Current: 22.73
10.29
24.34
Price-to-Operating-Cash-Flow 19.06
JNJ's Price-to-Operating-Cash-Flow is ranked higher than
50% of the 281 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 19.13 vs. JNJ: 19.06 )
Ranked among companies with meaningful Price-to-Operating-Cash-Flow only.
JNJ' s Price-to-Operating-Cash-Flow Range Over the Past 10 Years
Min: 8.99  Med: 13.15 Max: 19.52
Current: 19.06
8.99
19.52
EV-to-EBIT 16.96
JNJ's EV-to-EBIT is ranked higher than
61% of the 563 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 20.48 vs. JNJ: 16.96 )
Ranked among companies with meaningful EV-to-EBIT only.
JNJ' s EV-to-EBIT Range Over the Past 10 Years
Min: 7.8  Med: 13.1 Max: 18.2
Current: 16.96
7.8
18.2
EV-to-EBITDA 14.34
JNJ's EV-to-EBITDA is ranked higher than
59% of the 591 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 17.55 vs. JNJ: 14.34 )
Ranked among companies with meaningful EV-to-EBITDA only.
JNJ' s EV-to-EBITDA Range Over the Past 10 Years
Min: 6.7  Med: 11 Max: 15
Current: 14.34
6.7
15
PEG Ratio 2.49
JNJ's PEG Ratio is ranked lower than
59% of the 314 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.97 vs. JNJ: 2.49 )
Ranked among companies with meaningful PEG Ratio only.
JNJ' s PEG Ratio Range Over the Past 10 Years
Min: 1.19  Med: 1.83 Max: 27.59
Current: 2.49
1.19
27.59
Shiller PE Ratio 26.21
JNJ's Shiller PE Ratio is ranked higher than
69% of the 197 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 38.91 vs. JNJ: 26.21 )
Ranked among companies with meaningful Shiller PE Ratio only.
JNJ' s Shiller PE Ratio Range Over the Past 10 Years
Min: 15.57  Med: 21.25 Max: 29.71
Current: 26.21
15.57
29.71
Current Ratio 2.52
JNJ's Current Ratio is ranked higher than
52% of the 795 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.40 vs. JNJ: 2.52 )
Ranked among companies with meaningful Current Ratio only.
JNJ' s Current Ratio Range Over the Past 10 Years
Min: 1.2  Med: 1.96 Max: 3.08
Current: 2.52
1.2
3.08
Quick Ratio 2.17
JNJ's Quick Ratio is ranked higher than
56% of the 795 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.84 vs. JNJ: 2.17 )
Ranked among companies with meaningful Quick Ratio only.
JNJ' s Quick Ratio Range Over the Past 10 Years
Min: 0.94  Med: 1.5 Max: 2.68
Current: 2.17
0.94
2.68
Days Inventory 141.70
JNJ's Days Inventory is ranked lower than
63% of the 713 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 117.36 vs. JNJ: 141.70 )
Ranked among companies with meaningful Days Inventory only.
JNJ' s Days Inventory Range Over the Past 10 Years
Min: 100.19  Med: 110.33 Max: 141.7
Current: 141.7
100.19
141.7
Days Sales Outstanding 62.20
JNJ's Days Sales Outstanding is ranked higher than
62% of the 651 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 74.70 vs. JNJ: 62.20 )
Ranked among companies with meaningful Days Sales Outstanding only.
JNJ' s Days Sales Outstanding Range Over the Past 10 Years
Min: 53.94  Med: 57.41 Max: 62.2
Current: 62.2
53.94
62.2
Days Payable 102.10
JNJ's Days Payable is ranked higher than
69% of the 597 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 70.86 vs. JNJ: 102.10 )
Ranked among companies with meaningful Days Payable only.
JNJ' s Days Payable Range Over the Past 10 Years
Min: 98.27  Med: 111.33 Max: 147.94
Current: 102.1
98.27
147.94

Dividend & Buy Back

vs
industry
vs
history
Dividend Yield % 2.42
JNJ's Dividend Yield % is ranked higher than
73% of the 691 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.58 vs. JNJ: 2.42 )
Ranked among companies with meaningful Dividend Yield % only.
JNJ' s Dividend Yield % Range Over the Past 10 Years
Min: 2.05  Med: 2.85 Max: 3.84
Current: 2.42
2.05
3.84
Dividend Payout Ratio 0.54
JNJ's Dividend Payout Ratio is ranked lower than
74% of the 406 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 0.33 vs. JNJ: 0.54 )
Ranked among companies with meaningful Dividend Payout Ratio only.
JNJ' s Dividend Payout Ratio Range Over the Past 10 Years
Min: 0.39  Med: 0.51 Max: 0.65
Current: 0.54
0.39
0.65
3-Year Dividend Growth Rate 6.70
JNJ's 3-Year Dividend Growth Rate is ranked higher than
50% of the 302 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 6.90 vs. JNJ: 6.70 )
Ranked among companies with meaningful 3-Year Dividend Growth Rate only.
JNJ' s 3-Year Dividend Growth Rate Range Over the Past 10 Years
Min: 6.7  Med: 13.4 Max: 17.5
Current: 6.7
6.7
17.5
Forward Dividend Yield % 2.49
JNJ's Forward Dividend Yield % is ranked higher than
70% of the 643 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.71 vs. JNJ: 2.49 )
Ranked among companies with meaningful Forward Dividend Yield % only.
N/A
5-Year Yield-on-Cost % 3.39
JNJ's 5-Year Yield-on-Cost % is ranked higher than
70% of the 846 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.18 vs. JNJ: 3.39 )
Ranked among companies with meaningful 5-Year Yield-on-Cost % only.
JNJ' s 5-Year Yield-on-Cost % Range Over the Past 10 Years
Min: 2.88  Med: 4 Max: 5.39
Current: 3.39
2.88
5.39
3-Year Average Share Buyback Ratio 1.20
JNJ's 3-Year Average Share Buyback Ratio is ranked higher than
94% of the 477 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: -4.30 vs. JNJ: 1.20 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
JNJ' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -4.3  Med: 0.1 Max: 2.3
Current: 1.2
-4.3
2.3

Valuation & Return

vs
industry
vs
history
Price-to-Tangible-Book 22.64
JNJ's Price-to-Tangible-Book is ranked lower than
94% of the 701 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 3.54 vs. JNJ: 22.64 )
Ranked among companies with meaningful Price-to-Tangible-Book only.
JNJ' s Price-to-Tangible-Book Range Over the Past 10 Years
Min: 4.5  Med: 9.3 Max: 22.94
Current: 22.64
4.5
22.94
Price-to-Intrinsic-Value-Projected-FCF 1.82
JNJ's Price-to-Intrinsic-Value-Projected-FCF is ranked higher than
58% of the 329 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.29 vs. JNJ: 1.82 )
Ranked among companies with meaningful Price-to-Intrinsic-Value-Projected-FCF only.
JNJ' s Price-to-Intrinsic-Value-Projected-FCF Range Over the Past 10 Years
Min: 0.84  Med: 1.61 Max: 3.6
Current: 1.82
0.84
3.6
Price-to-Intrinsic-Value-DCF (Earnings Based) 2.10
JNJ's Price-to-Intrinsic-Value-DCF (Earnings Based) is ranked lower than
72% of the 87 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.51 vs. JNJ: 2.10 )
Ranked among companies with meaningful Price-to-Intrinsic-Value-DCF (Earnings Based) only.
N/A
Price-to-Median-PS-Value 1.60
JNJ's Price-to-Median-PS-Value is ranked lower than
78% of the 718 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.08 vs. JNJ: 1.60 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
JNJ' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.49  Med: 1.02 Max: 1.88
Current: 1.6
0.49
1.88
Price-to-Peter-Lynch-Fair-Value 2.37
JNJ's Price-to-Peter-Lynch-Fair-Value is ranked lower than
71% of the 207 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.59 vs. JNJ: 2.37 )
Ranked among companies with meaningful Price-to-Peter-Lynch-Fair-Value only.
JNJ' s Price-to-Peter-Lynch-Fair-Value Range Over the Past 10 Years
Min: 0.53  Med: 1.73 Max: 4.26
Current: 2.37
0.53
4.26
Price-to-Graham-Number 4.76
JNJ's Price-to-Graham-Number is ranked lower than
85% of the 484 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.10 vs. JNJ: 4.76 )
Ranked among companies with meaningful Price-to-Graham-Number only.
JNJ' s Price-to-Graham-Number Range Over the Past 10 Years
Min: 1.67  Med: 2.98 Max: 5.97
Current: 4.76
1.67
5.97
Earnings Yield (Greenblatt) % 5.88
JNJ's Earnings Yield (Greenblatt) % is ranked higher than
73% of the 820 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.97 vs. JNJ: 5.88 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
JNJ' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: 5.5  Med: 7.6 Max: 12.9
Current: 5.88
5.5
12.9
Forward Rate of Return (Yacktman) % 13.23
JNJ's Forward Rate of Return (Yacktman) % is ranked higher than
59% of the 381 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 9.46 vs. JNJ: 13.23 )
Ranked among companies with meaningful Forward Rate of Return (Yacktman) % only.
JNJ' s Forward Rate of Return (Yacktman) % Range Over the Past 10 Years
Min: 1.7  Med: 13.5 Max: 17.7
Current: 13.23
1.7
17.7

More Statistics

Revenue (TTM) (Mil) $72,174.00
EPS (TTM) $ 5.95
Beta0.68
Short Percentage of Float0.59%
52-Week Range $109.32 - 137.00
Shares Outstanding (Mil)2,693.83

Analyst Estimate

Dec17 Dec18 Dec19
Revenue (Mil $) 75,475 78,398 82,695
EPS ($) 7.10 7.59 8.05
EPS without NRI ($) 7.10 7.59 8.05
EPS Growth Rate
(Future 3Y To 5Y Estimate)
3.71%
Dividends per Share ($) 3.35 3.55 3.78
» More Articles for JNJ

Headlines

Articles On GuruFocus.com
Paulson Dives Deeper Into Valeant With Increased Holding Jun 27 2017 
US Market Indexes Lower, Technology Stock Volatility a Factor Jun 27 2017 
General Mills to Release 4th-Quarter, Full-Fiscal 2017 Results Jun 27 2017 
Warren Buffett Interprets the State of the Economy on PBS Newshour Jun 27 2017 
Office Space Provider Is a Good Stock to Follow Jun 27 2017 
Don't Lose Your Faith in Cisco Systems Jun 27 2017 
The Future of Value Investing Jun 27 2017 
Quotes From 2 of the World's Greatest Value Investors Jun 27 2017 
Extracts From the Bible of Value Investing Jun 27 2017 
Autonomous Driving Offers No Easy Path for Investors Jun 27 2017 

More From Other Websites
This is the One Company That Both Trump and Clinton Voters Love Equally Jun 28 2017
Healthcare: ACA Repeal Efforts Unlikely to Yield Major Legislative Changes Jun 28 2017
Cramer Remix: Why age is just a number when it comes to i... Jun 27 2017
Pfizer’s Valuation as of June 22, 2017 Jun 27 2017
The Forgotten $35 Billion U.S. Healthcare Problem Jun 27 2017
3 Top Dividend Aristocrats for the Long Term Jun 27 2017
This ‘classic’ Dow stock has come too far, too fast: Technician Jun 26 2017
J&J CEO Gorsky on M&A, Health Care, Tax Reform Jun 26 2017
J&J CEO Gorsky Says Health Care Labor Market Is Tight Jun 26 2017
J&J CEO Gorsky Says Health Care Needs 10-20 Years of Work Jun 26 2017
J&J CEO Gorsky Says U.S. Tax Reform Is Essential Jun 26 2017
3 Dividend Stocks for Smart Investors Jun 25 2017
3 Reasons to Buy Celgene Stock and Never Sell Jun 25 2017
Portola Pharmaceuticals' FDA Nod Could Spark M&A Interest Jun 24 2017
The 3 Best Dividend Stocks for Beginning Investors Jun 24 2017
Trump’s adds NY Jets owner to diplomatic roster Jun 23 2017
A New ETF For Low Vol ETFs Jun 23 2017
Dow 30 Stock Roundup: Boeing Bags Big Orders at Paris Air Show; Wal-Mart to Buy Bonobos Jun 23 2017
How Alphabet’s YouTube’s Ad Boycotters Fared Jun 23 2017
Healthcare ETF (IYH) Hits New 52-Week High Jun 23 2017

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)

GF Chat

{{numOfNotice}}